Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Japanese study of 177Lu-PSMA-617 in progressive PSMA-positive metastatic castration-resistant prostate cancer
jRCT2041210123Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicity and Overall Response Rate. Started Jan 2022; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2041210123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210123.